Does APC/C\textsuperscript{CDH1} control the human brain size?
An Editorial Highlight for 'A novel human Cdh1 mutation impairs anaphase-promoting complex/cyclosome (APC/C) activity resulting in microcephaly, psychomotor retardation, and epilepsy' on page 103.

Maike F. Dohrn* and Juan P. Bolaños†‡

*Department of Neurology, Medical Faculty, RWTH Aachen University, Aachen, Germany
†Institute of Functional Biology and Genomics, CSIC, University of Salamanca, Salamanca, Spain
‡Centro de Investigación Biomédica en Red sobre Fragilidad y Envejecimiento Saludable (CIBERFES), Institute of Biomedical Research of Salamanca, Salamanca, Spain

Abstract
This editorial highlights a study by Rodriguez, Sanchez-Moran et al. (2019) in the current issue of the Journal of Neurochemistry, in which the authors describe a microcephalic boy carrying the novel heterozygous de novo missense mutation c.560A>G; p.Asp187Gly in Cdh1/Fzr1 encoding the APC/C E3-ubiquitin ligase cofactor CDH1. A functional characterization of mutant APC/C\textsuperscript{CDH1} confirms an aberrant division of neural progenitor cells, a condition known to determine the mouse brain cortex size. These data suggest that APC/C\textsuperscript{CDH1} may contribute to the regulation of the human brain size.

Microcephaly is a brain development disorder resulting in a reduced size of both brain and head (Barkovich et al. 2012). Although the causes of microcephaly are diverse, many of them are genetic, a circumstance that has enabled to understand the physiology of cortical development (Thornton and Woods 2009). Some of these genes are involved in the control of mitotic function suggesting that the disease pathology is associated with aberrant neural progenitor cell proliferation. The anaphase-promoting complex/cyclosome (APC/C) is an E3 ubiquitin ligase essential for the regulation of cell division (Garcia-Higuera et al. 2008). Depending on the cell cycle stage, APC/C requires binding to either CDC20 or CDH1 (also known as Fzr1) for its full activity. To exit mitosis, APC/C needs to be activated by CDH1, and the APC/C\textsuperscript{CDH1} complex remains active during the G\textsubscript{1} phase of the cell cycle as well as in G\textsubscript{0} (postmitotic cells) (Garcia-Higuera et al. 2008). As postmitotic cells, fully differentiated neurons show a highly active APC/C\textsuperscript{CDH1} complex, which continuously promotes the degradation of proteins such as 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) (Herrero-Mendez et al. 2009), ROCK2 (Bobo-Jimenez et al. 2017), and cyclin B1 (Almeida et al. 2005) to regulate energy metabolism, dendritic integrity, memory, and survival (Bolaños 2016). Interestingly, during mouse brain development, APC/C\textsuperscript{CDH1} was found to control the division of neural progenitor cells to determine the correct size of the brain cortex (Delgado-Esteban et al. 2013). Indeed, genetic deletion of Cdh1 specifically during the embryonic stage impairs neurogenesis causing microcephaly (Delgado-Esteban et al. 2013), thus posing the loss of APC/C\textsuperscript{CDH1} function as a potential cause of human microcephaly.

Our current knowledge on APC/C\textsuperscript{CDH1} function in the brain has been built on research performed in cellular and non-human organismal models. Hence, the actual importance of this ubiquitin ligase in human brain pathophysiology has so far remained uncertain. In the current issue of the Journal of...
Neurochemistry. Rodríguez et al. (2019) report the first case of a putatively pathogenic, heterozygous missense mutation in Cdh1 causing microcephaly, mental retardation, spasticity, and epilepsy in a 4-year-old boy. Assuming a functionally important role in brain development, the authors searched for potentially disease-causing variants in the Cdh1 gene screening several hundreds of whole exomes, all of which were previously sequenced in individuals with neurodevelopmental disorders of a potentially genetic origin. The heterozygous missense mutation c.560A>G; p.Asp187Gly was verified to have arisen de novo from healthy, non-consanguineous parents of Spanish descend (Rodriguez et al. 2019). Besides severe antenatal microcephaly, the boy showed psychomotor retardation and refractory epilepsy, well-known signs of microcephaly. To link the p.Asp187Gly mutation in Cdh1 with the microcephaly phenotype, the authors functionally characterized the mutant protein. The finding that CDH1 protein abundance was substantially lower in the patient’s leukocytes compared with those isolated from his parents (Rodriguez et al. 2019) strongly suggests an impaired E3 ubiquitin ligase APC/C activity. To confirm this, the authors engineered, by site-directed mutagenesis, the mutant (c.560A>G) full-length Cdh1 cDNA. The implementation of mutant Cdh1 in human HEK293T cells confirmed the reduced expression of CDH1 protein (Rodriguez et al. 2019). To ascertain whether APC/C activity was impaired, the authors determined the protein abundances of two well-known substrates of APC/C(CDH1), namely cyclin B1 (Almeida et al. 2005) and PFKFB3 (Herrero-Mendez et al. 2009). Both protein abundances were found to be significantly increased in cells transfected with mutant Cdh1 when compared with cells expressing wild-type CDH1 (Rodriguez et al. 2019). Confocal imaging characterization of HEK293T cells expressing either the mutant or the wild-type CDH1 protein confirmed exclusive nuclear localization of the mutant form (Rodriguez et al. 2019), a condition compatible with low CDH1 protein stability (Nagai et al. 2018). Moreover, analysis of the cell cycle distribution revealed a severe delay in the exit from mitosis in HEK293T cells expressing mutant CDH1 (Rodriguez et al. 2019). Thus, the functional characterization of human cells carrying mutant CDH1 confirms the typical features of APC/C(CDH1) loss of function. Finally, the authors expressed either the mutant or the wild-type CDH1 in mouse neural progenitor cells isolated from a Cdh1-null genetic background. The analysis of cell cycle revealed an enlargement of the S-phase in those cells expressing the mutant CDH1 (Rodriguez et al. 2019), that is, the typical feature of neurogenesis impairment causing microcephaly previously reported by the authors via genetic Cdh1 ablation (Delgado-Esteban et al. 2013). Altogether, these sets of elegant experiments strongly indicate that the novel missense mutation c.560A>G; p.Asp187Gly identified in human Cdh1 results in APC/C loss of activity causing the typical neurogenesis impairment of microcephaly (Fig. 1).

It is intriguing, however, that this heterozygous Cdh1 mutation is sufficient to develop such a severe phenotypic impact (Rodriguez et al. 2019). Primary microcephaly has already been associated with disturbed mitosis, but the underlying mode of inheritance has typically been autosomal recessive (Thornton and Woods, 2009; Faheem et al., 2015). Furthermore, a dominant negative effect is usually not expected in a loss of function pathomechanism. The authors explain that this observation might be ascribed to the low intolerance score of the Cdh1 gene (Firth et al. 2009; Lek et al., 2016) indicating that the loss of function of one mutated allele cannot be compensated by the wild type (Rodriguez et al. 2019). While this may be a suitable explanation, it should be noticed that heterozygous Cdh1-knockout mice (Cdh1<sup>+/−</sup>) show no alterations in the cell division of neural progenitors, which are identical to that found in the wild-type animals (Delgado-Esteban et al. 2013). These data suggest that the loss of mutant p.Asp187Gly CDH1 protein may not be sufficient to explain the lack of APC/C function. One methodological limitation of this work might be that additional, regulatory variants placed within an intronic region of Cdh1 could not be excluded by whole exome sequencing. Whether there is another functionally relevant splice mutation lingering on the trans allele in this patient remains to be elucidated. Co-segregation analyses, which are in principle an important step...
Acknowledgments and conflicts of interest disclosure

JPB is funded by MINECO (SAF2016-78114-R), Instituto de Salud Carlos III (CIBERFES CB16/1000282), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomediácia 2017 Fundación BBVA, and Fundación Ramón Areces. JPB is Handling Editor of the Journal of Neurochemistry. MFD declares that she has no conflict of interests.

References

Almeida A., Bolaños J. P. and Moreno S. (2005) Cdh1/Hct1-APC is essential for the survival of postmitotic neurons. J. Neurosci. 25, 8115–8121.

Barkovich A. J., Guerrini R., Kuzniecky R. I., Jackson G. D. and Dobyns W. B. (2012) A developmental and genetic classification for malformations of cortical development: update 2012. Brain 135, 1348–1369.

Bobo-Jimenez V., Delgado-Esteban M., Angibaud J., Sanchez-Moran I., de la Fuente A., Yajeya J., Nägerl U. V., Castillo J., Bolaños J. P. and Almeida A. (2017) APC/C(Cdh1)-Rock2 pathway controls dendritic integrity and memory. Proc. Natl Acad. Sci. USA 114, 4513–4518.

Bolaños J. P. (2016) Bioenergetics and redox adaptations of astrocytes to neuronal activity. J. Neurochem. 139, 115–125.

Delgado-Esteban M., Garcia-Higuera I., Maestre C., Moreno S. and Almeida A. (2013) APC/C-Cdh1 coordinates neurogenesis and cortical size during development. Nat. Commun. 4, 2879.

Faheem M., Naseer M. I., Rasool M., et al (2015) Molecular genetics of human primary microcephaly: an overview. BMC Med. Genomics 8, S4.

Firth H. V., Richards S. M., Bevan A. P., Clayton S., Corpas M., Rajan D., Van Vooren S., Moreau Y., Pettet R. M. and Carter N. P. (2009) DECIPHER: database of chromosomal imbalance and phenotype in humans using ensemble resources. Am. J. Hum. Genet. 84, 524–533.

Garcia-Higuera I., Manchado E., Dabús P., Cañamero M., Mendez J., Moreno S. and Malumbres M. (2008) Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat. Cell Biol. 10, 802–811.

Herrero-Mendez A., Almeida A., Fernandez E., Maestre C., Moncada S. and Bolaños J. P. (2009) The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat. Cell Biol. 11, 747–752.

Lek M., Karczewski K. J., Minikel E. V. et al. (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291.

Nagai M., Shibata A. and Ushimaru T. (2018) Cdh1 degradation is mediated by APC/C-Cdh1 and SCF-Cdc4 in budding yeast. Biochem. Biophys. Res. Commun. 506, 932–938.

Rodríguez C., Sánchez-Morón I., Álvaro S., Tirado P., Fernández-Mayoralas D. M., Calleja-Pérez B., Almeida A. and Fernández-Jaén A. (2019) A novel human Cdh1 mutation impairs anaphase promoting complex/cyclosome (APC/C) activity resulting in microcephaly, psychomotor retardation and epilepsy. J. Neurochem. 151, 103–115.

Thornton G. K. and Woods C. G. (2009) Primary microcephaly: do all roads lead to Rome? Trends Genet 25, 501–510.